Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02966665 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

: Vascular Function in Health and Disease

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 years 11 months later Aug 2026 → Aug 2030
See other at-risk trials from D. Walter Wray

Record History

See every version on ClinicalTrials.gov ↗

  1. Notable Primary and study completion pushed from Aug 2026 to Aug 2030 Show 4 more changesShow less
    • Sponsor changed: Russell Richardson to D. Walter Wray
    • Eligibility criteria expanded, about 18 words
    • Study description revised
    • Study site revised
  2. Notable Primary and study completion dates: Aug 2025 to Aug 2026v11
  3. Minor 4 versions Re-verified since Sep 15, 2021, no change to tracked fieldsv7-v10
  4. Notable Primary and study completion dates: Aug 2020 to Aug 2025v6
  5. Minor 3 versions Re-verified since Mar 16, 2018, no change to tracked fieldsv3-v5
  6. Notable Primary endpoint revised
    • Interventions: Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine (Other), Angiotensin-II, Valsartan (Other), BQ-123… to Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine (Drug), Angiotensin-II, Valsartan (Other), BH4, L-NMMA…
    • Secondary endpoints: 2 to 3
    v2
  7. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
8,786 trials monitored
See 412 trials at risk
1,995 trials monitored
See 111 trials at risk
1,925 trials monitored
See 99 trials at risk
and 1 more disease
Many control mechanisms exist which successfully match the supply of blood with the metabolic demand of various tissues under wide-ranging conditions. One primary regulator of vasomotion and thus perfusion to the muscle tissue is the host of chemical factors originating from the vascular endothelium and the muscle tissue, which collectively sets the level of vascular tone. With advancing age and in many disease states, deleterious adaptations in the production and sensitivity of these vasodilator and vasoconstrictor substances may be observed, leading to a reduction in skeletal muscle blood flow and compromised perfusion to the muscle tissue. Adequate perfusion is particularly important during exercise to meet the increased metabolic demand of the exercising tissue, and thus any condition that reduces tissue perfusion may limit the capacity for physical activity. As it is now well established that regular physical activity is a key component in maintaining cardiovascular health with advancing age, there is a clear need for further studies in populations where vascular dysfunction is compromised, with the goal of identifying the mechanisms responsible for the dysfunction and exploring whether these maladaptations may be remediable. Thus, to better understand the etiology of these vascular adaptations in health and disease, the current proposal is designed to study changes in vascular function with advancing age, and also examine peripheral vascular changes in patients suffering from chronic obstructive pulmonary disease (COPD), Sepsis, Pulmonary Hypertension, and cardiovascular disease. While there are clearly a host of vasoactive substances which collectively act to govern vasoconstriction both at rest and during exercise, four specific pathways that may be implicated have been identified in these populations: Angiotensin-II (ANG-II), Endothelin-1 (ET-1), Nitric Oxide (NO), and oxidative stress.
Trial Details
NCT Number NCT02966665
Lead Sponsor D. Walter Wray
Conditions
(from sponsor)
Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure, Hypertension
Related terms Familial Primary Pulmonary Hypertension, Heart Failure, Hypertension, Pulmonary Disease, Chronic Obstructive
Enrollment 420 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov